icryo semaglutide Medical Weight Loss | icryo semaglutide Semaglutide Receives FDA

Repeatedly injecting in the same location can cause lipohypertrophy, a buildup of scar-like fatty tissue under the skin

Reported complications described in some GLP-1 drug claims have included: Severe or persistent gastrointestinal symptoms , such as ongoing nausea, vomiting, or abdominal pain Delayed stomach emptying (gastroparesis) , which has been described by some individuals as involving bloating, nausea, vomiting, or difficulty tolerating food Intestinal complications , including reduced bowel activity (ileus), which may involve abdominal discomfort, cramping, or vomiting Gallbladder-related conditions , such as gallstones or gallbladder inflammation Blood-clot-related conditions , including deep vein thrombosis or pulmonary embolism, described in some reports and legal filings Vision-related problems , including reports involving non-arteritic anterior ischemic optic neuropathy (NAION) discussed in connection with semaglutide in certain contexts Not everyone who takes a GLP-1 medication experiences these issues, and the relationship between GLP-1 drugs and reported complications continues to be evaluated in legal proceedings

States that provide coverage for GLP-1 drugs are blowing holes in their budget

doi: 10.1016/j.diabres.2020.108087 87 Committee for Medicinal Products for Human Use (CHMP)